ACUTE EFFECTS OF OCTREOTIDE, A LONG-ACTING SOMATOSTATIN ANALOG, ON THE INSULINEMIC AND GLYCEMIC RESPONSES TO A MIXED MEAL IN PATIENTS WITH ESSENTIAL OBESITY - A DOSE-RESPONSE STUDY
A. Giustina et al., ACUTE EFFECTS OF OCTREOTIDE, A LONG-ACTING SOMATOSTATIN ANALOG, ON THE INSULINEMIC AND GLYCEMIC RESPONSES TO A MIXED MEAL IN PATIENTS WITH ESSENTIAL OBESITY - A DOSE-RESPONSE STUDY, Diabetes, nutrition & metabolism, 7(1), 1994, pp. 35-41
We investigated the effects of single different doses of the long acti
ng somatostatin analog octreotide on the insulinemic and glycemic resp
onses to a mixed meal in eleven patients with essential obesity (10F-1
M; age 42.2+/-4.1 years; BMI 38.1+/-1.6 kg/m(2); waist/hip ratio 0.9+/
-0.04). They underwent four different tests according to a randomized,
single blind design: at 07.30 hr the patients received (a) normal sal
ine (1 ml s.c.); octreotide (b) 25 mu g s.c. or (c) 50 mu g s.c. or (d
) 100 mu g s.c. From 08.00 to 08.15 hr the patients were given a fluid
mixed meal (375 kcal: 53.3% carbohydrate, 30% fat, 16.7% protein). Me
an blood glucose peak after placebo was: 125+/-6 mg/dl, p<0.05 vs base
line (82+/-4 mg/dl). Blood glucose peaks after the meal were increased
even if not significantly as compared to placebo either after octreot
ide 100 mu g (169+/-11 mg/dl) or 50 mu g (167+/-9 mg/dl) or 25 mu g (1
58+/-10 mg/dl). Mean baseline (07.00 and 07.30 hr samples) fasting ins
ulin levels were significantly lowered with respect to placebo (23+/-4
mu U/ml). by the administration of each dose of octreotide (25 mu g:
1.2+/-0.9; 50 mu g: 1.9+/-0.9; 100 mu g: 1.7+/-0.7 mu U/ml). Following
the administration of the mixed meal a highly significant increase in
serum insulin levels after saline was observed (peak: 106.9+/-16 mu U
/ml). After octreotide serum insulin peaks after the meal were signifi
cantly lower as compared to saline either after octreotide 100 mu g (2
0.3+/-4.1 mu U/ml) or 50 mu g (23+/-3.4 mu U/ml) or 25 mu g (36+/-12 m
u U/ml) without significant differences between each regimen. It can b
e hypothesized that, at least in a part of obese patients, the adminis
tration of even low doses of octreotide may result on one side in a di
rect inhibitory effect on insulin secretion at the pancreatic level an
d on the other in a facilitatory action on the effects of insulin at t
he peripheral level.